Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 23-08-2023 | Pseudomonas | Original Article

A novel lytic phage exhibiting a remarkable in vivo therapeutic potential and higher antibiofilm activity against Pseudomonas aeruginosa

Authors: Aliaa Abdelghafar, Amira El-Ganiny, Ghada Shaker, Momen Askoura

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 10/2023

Abstract

Background

Pseudomonas aeruginosa is a nosocomial bacterium responsible for variety of infections. Inappropriate use of antibiotics could lead to emergence of multidrug-resistant (MDR) P. aeruginosa strains. Herein, a virulent phage; vB_PaeM_PS3 was isolated and tested for its application as alternative to antibiotics for controlling P. aeruginosa infections.

Methods

Phage morphology was observed using transmission electron microscopy (TEM). The phage host range and efficiency of plating (EOP) in addition to phage stability were analyzed. One-step growth curve was performed to detect phage growth kinetics. The impact of isolated phage on planktonic cells and biofilms was assessed. The phage genome was sequenced. Finally, the therapeutic potential of vB_PaeM_PS3 was determined in vivo.

Results

Isolated phage has an icosahedral head and a contractile tail and was assigned to the family Myoviridae. The phage vB_PaeM_PS3 displayed a broad host range, strong bacteriolytic ability, and higher environmental stability. Isolated phage showed a short latent period and large burst size. Importantly, the phage vB_PaeM_PS3 effectively eradicated bacterial biofilms. The genome of vB_PaeM_PS3 consists of 93,922 bp of dsDNA with 49.39% G + C content. It contains 171 predicted open reading frames (ORFs) and 14 genes as tRNA. Interestingly, the phage vB_PaeM_PS3 significantly attenuated P. aeruginosa virulence in host where the survival of bacteria-infected mice was markedly enhanced following phage treatment. Moreover, the colonizing capability of P. aeruginosa was markedly impaired in phage-treated mice as compared to untreated infected mice.

Conclusion

Based on these findings, isolated phage vB_PaeM_PS3 could be potentially considered for treating of P. aeruginosa infections.

Available only for authorised users

Crone S, Vives-Flórez M, Kvich L, Saunders AM, Malone M, Nicolaisen MH et al (2020) The environmental occurrence of Pseudomonas aeruginosa. APMIS 128(3):220–231. https://doi.org/10.1111/apm.13010CrossRefPubMed

Rossi E, La Rosa R, Bartell JA, Marvig RL, Haagensen JA, Sommer LM et al (2021) Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nat Rev Microbiol 19(5):331–342. https://doi.org/10.1038/s41579-020-00477-5CrossRefPubMed

Jurado-Martín I, Sainz-Mejías M, McClean S (2021) Pseudomonas aeruginosa: An audacious pathogen with an adaptable arsenal of virulence factors. Int J Mol Sci 22(6):3128. https://doi.org/10.3390/ijms22063128CrossRefPubMedPubMedCentral

Breidenstein EB, de la Fuente-Núñez C, Hancock RE (2011) Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19(8):419–426. https://doi.org/10.1016/j.tim.2011.04.005CrossRefPubMed

Daikos GL, da Cunha CA, Rossolini GM, Stone GG, Baillon-Plot N, Tawadrous M et al (2021) Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa. Antibiotics 10(9):1126. https://doi.org/10.3390/antibiotics10091126CrossRefPubMedPubMedCentral

Pang Z, Raudonis R, Glick BR, Lin T-J, Cheng Z (2019) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 37(1):177–192. https://doi.org/10.1016/j.biotechadv.2018.11.013CrossRefPubMed

Hancock RE, Speert DP (2000) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 3(4):247–255. https://doi.org/10.1054/drup.2000.0152CrossRefPubMed

Ma L, Conover M, Lu H, Parsek MR, Bayles K, Wozniak DJ (2009) Assembly and development of the Pseudomonas aeruginosa biofilm matrix. PLoS Pathog 5(3):e1000354. https://doi.org/10.1371/journal.ppat.1000354CrossRefPubMedPubMedCentral

Spoering AL, Lewis K (2001) Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 183(23):6746–6751. https://doi.org/10.1128/JB.183.23.6746-6751.2001CrossRefPubMedPubMedCentral

10.

Forti F, Roach DR, Cafora M, Pasini ME, Horner DS, Fiscarelli EV et al (2018) Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob Agents Chemother 62(6):e02573-e2617. https://doi.org/10.1128/AAC.02573-17CrossRefPubMedPubMedCentral

11.

Waters EM, Neill DR, Kaman B, Sahota JS, Clokie MR, Winstanley C et al (2017) Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 72(7):666–667. https://doi.org/10.1136/thoraxjnl-2016-209265CrossRefPubMed

12.

Clokie MR, Millard AD, Letarov AV, Heaphy S (2011) Phages in nature. Bacteriophage 1(1):31–45. https://doi.org/10.4161/bact.1.1.14942CrossRefPubMedPubMedCentral

13.

Golkar Z, Bagasra O, Pace DG (2014) Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. J Infect Dev Ctries 8(02):129–136. https://doi.org/10.3855/jidc.3573CrossRefPubMed

14.

Moelling K, Broecker F, Willy C (2018) A wake-up call: we need phage therapy now. Viruses 10(12):688. https://doi.org/10.3390/v10120688CrossRefPubMedPubMedCentral

15.

Khalifa L, Shlezinger M, Beyth S, Houri-Haddad Y, Coppenhagen-Glazer S, Beyth N et al (2016) Phage therapy against Enterococcus faecalis in dental root canals. J Oral Microbiol 8:32157. https://doi.org/10.3402/jom.v8.32157CrossRefPubMed

16.

Chang H-C, Chen C-R, Lin J-W, Shen G-H, Chang K-M, Tseng Y-H et al (2005) Isolation and characterization of novel giant Stenotrophomonas maltophilia phage φSMA5. App Environ Microbiol 71(3):1387–1393. https://doi.org/10.1128/AEM.71.3.1387-1393.2005CrossRef

17.

Abedon ST, García P, Mullany P, Aminov R (2017) Editorial: Phage Therapy: Past, Present and Future. Front Microbiol 8:981. https://doi.org/10.3389/fmicb.2017.00981CrossRefPubMedPubMedCentral

18.

Wittebole X, De Roock S, Opal SM (2014) A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5(1):226–235. https://doi.org/10.4161/viru.25991CrossRefPubMed

19.

Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L et al (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61(10):e00954-e1017. https://doi.org/10.1128/AAC.00954-17CrossRefPubMedPubMedCentral

20.

Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K et al (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25(5):730–733. https://doi.org/10.1038/s41591-019-0437-zCrossRefPubMedPubMedCentral

21.

Casey E, Van Sinderen D, Mahony J (2018) In vitro characteristics of phages to guide ‘real life’phage therapy suitability. Viruses 10(4):163. https://doi.org/10.3390/v10040163CrossRefPubMedPubMedCentral

22.

Tiwari BR, Kim S, Rahman M, Kim J (2011) Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models. J Microbiol 49:994–999. https://doi.org/10.1007/s12275-011-1512-4CrossRefPubMed

23.

Wroe JA, Johnson CT, García AJ (2020) Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo. J Biomed Mater Res A 108(1):39–49. https://doi.org/10.1002/jbm.a.36790CrossRefPubMed

24.

Garbe J, Wesche A, Bunk B, Kazmierczak M, Selezska K, Rohde C et al (2010) Characterization of JG024, a Pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions. BMC Microbiol 10(1):1–10. https://doi.org/10.1186/1471-2180-10-301CrossRef

25.

Oliveira VC, Bim FL, Monteiro RM, Macedo AP, Santos ES, Silva-Lovato CH et al (2020) Identification and characterization of new bacteriophages to control multidrug-resistant Pseudomonas aeruginosa biofilm on endotracheal tubes. Front Microbiol 11:580779. https://doi.org/10.3389/fmicb.2020.580779CrossRefPubMedPubMedCentral

26.

Alvi IA, Asif M, Tabassum R, Aslam R, Abbas Z, Rehman SU (2020) RLP, a bacteriophage of the family Podoviridae, rescues mice from bacteremia caused by multi-drug-resistant Pseudomonas aeruginosa. Arch Virol 165:1289–1297. https://doi.org/10.1007/s00705-020-04601-xCrossRefPubMed

27.

Yang Y, Shen W, Zhong Q, Chen Q, He X, Baker JL et al (2020) Development of a bacteriophage cocktail to constrain the emergence of phage-resistant Pseudomonas aeruginosa. Front Microbiol 11:327. https://doi.org/10.3389/fmicb.2020.00327CrossRefPubMedPubMedCentral

28.

Ceyssens P-J, Lavigne R, Mattheus W, Chibeu A, Hertveldt K, Mast J et al (2006) Genomic analysis of Pseudomonas aeruginosa phages LKD16 and LKA1: Establishment of the φKMV subgroup within the T7 supergroup. J Bacteriol 188(19):6924–6931. https://doi.org/10.1128/JB.00831-06CrossRefPubMedPubMedCentral

29.

Lerdsittikul V, Thongdee M, Chaiwattanarungruengpaisan S, Atithep T, Apiratwarrasakul S, Withatanung P et al (2022) A novel virulent Litunavirus phage possesses therapeutic value against multidrug resistant Pseudomonas aeruginosa. Sci Rep 12(1):21193. https://doi.org/10.1038/s41598-022-25576-6CrossRefPubMedPubMedCentral

30.

Tan D, Gram L, Middelboe M (2014) Vibriophages and their interactions with the fish pathogen Vibrio anguillarum. Appl Environ Microbiol 80(10):3128–3140. https://doi.org/10.1128/AEM.03544-13CrossRefPubMedPubMedCentral

31.

Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP (2009) Enumeration of Bacteriophages by Double Agar Overlay Plaque Assay. In: Clokie, M.R., Kropinski, A.M. (eds) Bacteriophages. Methods Mol Biol™, vol 501. Humana Press; 69–76 https://doi.org/10.1007/978-1-60327-164-6_7

32.

Gencay YE, Birk T, Sørensen MCH, Brøndsted L (2017) Methods for Isolation, Purification, and Propagation of Bacteriophages of Campylobacter jejuni . In: Butcher, J., Stintzi, A. (eds) Campylobacter jejuni. Methods Mol Biol, vol 1512. Humana Press, New York, NY; 19–28. https://doi.org/10.1007/978-1-4939-6536-6_3

33.

Essoh C, Blouin Y, Loukou G, Cablanmian A, Lathro S, Kutter E et al (2013) The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS One 8(4):e60575. https://doi.org/10.1371/journal.pone.0060575CrossRefPubMedPubMedCentral

34.

González-Villalobos E, Ribas-Aparicio RM, Montealegre GER, Belmont-Monroy L, Ortega-García Y, Aparicio-Ozores G et al (2021) Isolation and characterization of novel bacteriophages as a potential therapeutic option for Escherichia coli urinary tract infections. Appl Microbiol Biotechnol 105:5617–5629. https://doi.org/10.1007/s00253-021-11432-6CrossRefPubMedPubMedCentral

35.

Khan Mirzaei M, Nilsson AS (2015) Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS one 10(3):e0118557. https://doi.org/10.1371/journal.pone.0118557CrossRefPubMedPubMedCentral

36.

Shahin K, Bouzari M, Wang R (2018) Isolation, characterization and genomic analysis of a novel lytic bacteriophage vB_SsoS-ISF002 infecting Shigella sonnei and Shigella flexneri. J Med Microbiol 67(3):376–386. https://doi.org/10.1099/jmm.0.000683CrossRefPubMed

37.

Kropinski AM (2018) Practical Advice on the One-Step Growth Curve. In: Clokie, M., Kropinski, A., Lavigne, R. (eds) Bacteriophages. Methods Mol Biol, vol 1681. Humana Press, New York, NY; 41–47. https://doi.org/10.1007/978-1-4939-7343-9_3

38.

Peng S-Y, Chen L-K, Wu W-J, Paramita P, Yang P-W, Li Y-Z et al (2020) Isolation and characterization of a new phage infecting Elizabethkingia anophelis and evaluation of its therapeutic efficacy in vitro and in vivo. Front Microbiol 11:728. https://doi.org/10.3389/fmicb.2020.00728CrossRefPubMedPubMedCentral

39.

Horváth M, Kovács T, Koderivalappil S, Ábrahám H, Rákhely G, Schneider G (2020) Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant Klebsiella pneumoniae isolates. Sci Rep 10(1):5891. https://doi.org/10.1038/s41598-020-62691-8CrossRefPubMedPubMedCentral

40.

Wittmann J, Dreiseikelmann B, Rohde C, Rohde M, Sikorski J (2014) Isolation and characterization of numerous novel phages targeting diverse strains of the ubiquitous and opportunistic pathogen Achromobacterxylosoxidans. PLoS One 9(1):e86935. https://doi.org/10.1371/journal.pone.0086935CrossRefPubMedPubMedCentral

41.

Jo A, Ding T, Ahn J (2016) Synergistic antimicrobial activity of bacteriophages and antibiotics against Staphylococcus aureus. Food Sci Biotechnol 25:935–940. https://doi.org/10.1007/s10068-016-0153-0CrossRefPubMedPubMedCentral

42.

Brown J, Pirrung M, Dashboard MLAFQC (2017) integrates FastQC results into a web-based, interactive, and extensible FASTQ quality control tool. Bioinformatics 33(19):3137–3139. https://doi.org/10.1093/bioinformatics/btx373CrossRefPubMedPubMedCentral

43.

Wick RR, Judd LM, Gorrie CL, Holt KE (2017) Completing bacterial genome assemblies with multiplex MinION sequencing. Microb Genom 3(10):e000132. https://doi.org/10.1099/mgen.0.000132

44.

Gurevich A, Saveliev V, Vyahhi N, Tesler G (2013) QUAST: quality assessment tool for genome assemblies. Bioinformatics 29(8):1072–1075. https://doi.org/10.1093/bioinformatics/btt086CrossRefPubMedPubMedCentral

45.

Prokka ST (2014) rapid prokaryotic genome annotation. Bioinformatics 30(14):2068–2069. https://doi.org/10.1093/bioinformatics/btu153CrossRef

46.

McNair K, Aziz RK, Pusch GD, Overbeek R, Dutilh BE, Edwards R (2018) Phage Genome Annotation Using the RAST Pipeline. In: Clokie, M., Kropinski, A., Lavigne, R. (eds) Bacteriophages. Methods Mol Biol vol 1681. Humana Press, New York, NY; https://doi.org/10.1007/978-1-4939-7343-9_17.

47.

Stothard P, Wishart DS (2005) Circular genome visualization and exploration using CGView. Bioinformatics 21(4):537–539. https://doi.org/10.1093/bioinformatics/bti054CrossRefPubMed

48.

Chan PP, Lowe TM (2019) tRNAscan-SE: Searching for tRNA Genes in Genomic Sequences. In: Kollmar, M. (eds) Gene Prediction. Methods Mol Biol vol 1962. Humana, New York, NY; https://doi.org/10.1007/978-1-4939-9173-0_1

49.

Kumar S, Stecher G, Li M, Knyaz C, Tamura K (2018) MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 35(6):1547. https://doi.org/10.1093/molbev/msy096CrossRefPubMedPubMedCentral

50.

Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215(3):403–410. https://doi.org/10.1016/S0022-2836(05)80360-2CrossRefPubMed

51.

Sullivan MJ, Petty NK, Beatson SA (2011) Easyfig: a genome comparison visualizer. Bioinformatics 27(7):1009–1010. https://doi.org/10.1093/bioinformatics/btr039CrossRefPubMedPubMedCentral

52.

Krumsiek J, Arnold R, Rattei T (2007) Gepard: a rapid and sensitive tool for creating dotplots on genome scale. Bioinformatics 23(8):1026–1028. https://doi.org/10.1093/bioinformatics/btm039CrossRefPubMed

53.

Kropinski AM, Prangishvili D, Lavigne R (2009) Position paper: the creation of a rational scheme for the nomenclature of viruses of Bacteria and Archaea. Environ Microbiol 11(11):2775–2777. https://doi.org/10.1111/j.1462-2920.2009.01970.xCrossRefPubMed

54.

Gellatly S, Hancock R (2013) Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67(3):159–173. https://doi.org/10.1111/2049-632X.12033CrossRefPubMed

55.

Pires DP, Vilas Boas D, Sillankorva S, Azeredo J (2015) Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 89(15):7449–7456. https://doi.org/10.1128/JVI.00385-15CrossRefPubMedPubMedCentral

56.

Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre A-S, Lavigne R (2012) Learning from bacteriophages-advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci 13(8):699–722. https://doi.org/10.2174/138920312804871193CrossRefPubMedPubMedCentral

57.

Fernández L, Gutiérrez D, García P, Rodríguez A (2019) The perfect bacteriophage for therapeutic applications—a quick guide. Antibiotics 8(3):126. https://doi.org/10.3390/antibiotics8030126CrossRefPubMedPubMedCentral

58.

Swanson MM, Reavy B, Makarova KS, Cock PJ, Hopkins DW, Torrance L et al (2012) Novel bacteriophages containing a genome of another bacteriophage within their genomes. PloS one 7(7):e40683. https://doi.org/10.1371/journal.pone.0040683CrossRefPubMedPubMedCentral

59.

Turner D, Hezwani M, Nelson S, Salisbury V, Reynolds D (2012) Characterization of the Salmonella bacteriophage vB_SenS-Ent1. J Gen Virol 93(9):2046–2056. https://doi.org/10.1099/vir.0.043331-0CrossRefPubMed

60.

Capra M, Quiberoni A, Reinheimer J (2006) Phages of Lactobacillus casei/paracasei: response to environmental factors and interaction with collection and commercial strains. J Appl Microbiol 100(2):334–342. https://doi.org/10.1111/j.1365-2672.2005.02767.xCrossRefPubMed

61.

Jamalludeen N, Johnson RP, Friendship R, Kropinski AM, Lingohr EJ, Gyles CL (2007) Isolation and characterization of nine bacteriophages that lyse O149 enterotoxigenic Escherichia coli. Vet Microbiol 124(1–2):47–57. https://doi.org/10.1016/j.vetmic.2007.03.028CrossRefPubMed

62.

Akremi I, Merabishvili M, Jlidi M, Haj Brahim A, Ben Ali M, Karoui A et al (2022) Isolation and Characterization of Lytic Pseudomonas aeruginosa Bacteriophages Isolated from Sewage Samples from Tunisia. Viruses 14(11):2339. https://doi.org/10.3390/v14112339CrossRefPubMedPubMedCentral

63.

Abedon ST, Herschler TD, Stopar D (2001) Bacteriophage latent-period evolution as a response to resource availability. Appl Environ Microbiol 67(9):4233–4241. https://doi.org/10.1128/AEM.67.9.4233-4241.2001CrossRefPubMedPubMedCentral

64.

Coulon C, Vinogradov E, Filloux A, Sadovskaya I (2010) Chemical analysis of cellular and extracellular carbohydrates of a biofilm-forming strain Pseudomonas aeruginosa PA14. PLoS One 5(12):e14220. https://doi.org/10.1371/journal.pone.0014220CrossRefPubMedPubMedCentral

65.

Wei Q, Ma LZ (2013) Biofilm matrix and its regulation in Pseudomonas aeruginosa. Int J Mol Sci 14(10):20983–21005. https://doi.org/10.3390/ijms141020983CrossRefPubMedPubMedCentral

66.

Manohar P, Madurantakam Royam M, Loh B, Bozdogan B, Nachimuthu R, Leptihn S (2022) Synergistic effects of phage–antibiotic combinations against Citrobacter amalonaticus. ACS Infect Dis 8(1):59–65. https://doi.org/10.1021/acsinfecdis.1c00117CrossRefPubMed

67.

Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Chan H-K (2018) Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa. Int J Pharm 551(1–2):158–165. https://doi.org/10.1016/j.ijpharm.2018.09.024CrossRefPubMedPubMedCentral

68.

Motlagh AM, Bhattacharjee AS, Goel R (2016) Biofilm control with natural and genetically-modified phages. World J Microbiol Biotechnol 32:1–10. https://doi.org/10.1007/s11274-016-2009-4CrossRef

69.

Tian F, Li J, Nazir A, Tong Y (2021) Bacteriophage–a promising alternative measure for bacterial biofilm control. Infect Drug Resist 14:205–217CrossRefPubMedPubMedCentral

70.

Yan J, Mao J, Xie J (2014) Bacteriophage polysaccharide depolymerases and biomedical applications. BioDrugs 28(3):265–274. https://doi.org/10.1007/s40259-013-0081-yCrossRefPubMed

71.

Schmelcher M, Donovan DM, Loessner MJ (2012) Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7(10):1147–1171. https://doi.org/10.2217/fmb.12.97CrossRefPubMed

72.

Endersen L, Guinane CM, Johnston C, Neve H, Coffey A, Ross RP et al (2015) Genome analysis of Cronobacter phage vB_CsaP_Ss1 reveals an endolysin with potential for biocontrol of Gram-negative bacterial pathogens. J Gen Virol 96(2):463–477. https://doi.org/10.1099/vir.0.068494-0CrossRefPubMed

73.

Santos SB, Kropinski AM, Ceyssens P-J, Ackermann H-W, Villegas A, Lavigne R et al (2011) Genomic and proteomic characterization of the broad-host-range Salmonella phage PVP-SE1: creation of a new phage genus. J Virol 85(21):11265–11273. https://doi.org/10.1128/JVI.01769-10CrossRefPubMedPubMedCentral

74.

Bailly-Bechet M, Vergassola M, Rocha E (2007) Causes for the intriguing presence of tRNAs in phages. Genome Res 17(10):1486–1495CrossRefPubMedPubMedCentral

75.

Lu S, Le S, Tan Y, Zhu J, Li M, Rao X et al (2013) Genomic and proteomic analyses of the terminally redundant genome of the Pseudomonas aeruginosa phage PaP1: establishment of genus PaP1-like phages. PloS one 8(5):e62933. https://doi.org/10.1371/journal.pone.0062933CrossRefPubMedPubMedCentral

76.

Jun JW, Yun SK, Kim HJ, Chai JY, Park SC (2014) Characterization and complete genome sequence of a novel N4-like bacteriophage, pSb-1 infecting Shigella boydii. Res Microbiol 165(8):671–678. https://doi.org/10.1016/j.resmic.2014.09.006CrossRefPubMed

77.

Hagens S, Habel A, Von Ahsen U, Von Gabain A, Bläsi U (2004) Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 48(10):3817–3822. https://doi.org/10.1128/AAC.48.10.3817-3822.2004CrossRefPubMedPubMedCentral

78.

Jeon J, Yong D (2019) Two novel bacteriophages improve survival in Galleria mellonella infection and mouse acute pneumonia models infected with extensively drug-resistant Pseudomonas aeruginosa. Appl Environ Microbiol 85(9):e02900-e2918. https://doi.org/10.1128/AEM.02900-18CrossRefPubMedPubMedCentral

79.

Wright A, Hawkins C, Änggård E, Harper D (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin otolaryngol 34(4):349–357. https://doi.org/10.1111/j.1749-4486.2009.01973.xCrossRefPubMed

80.

Jault P, Leclerc T, Jennes S, Pirnay JP, Que Y-A, Resch G et al (2019) Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 19(1):35–45. https://doi.org/10.1016/S1473-3099(18)30482-1CrossRefPubMed

Title: A novel lytic phage exhibiting a remarkable in vivo therapeutic potential and higher antibiofilm activity against Pseudomonas aeruginosa
Authors: Aliaa Abdelghafar
Amira El-Ganiny
Ghada Shaker
Momen Askoura
Publication date: 23-08-2023
Publisher: Springer Berlin Heidelberg
Keywords: Pseudomonas
Pseudomonas Aeruginosa
Antibiotic
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 10/2023
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-023-04649-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2023

Three separate acquisitions of blaNDM-1 in three different bacterial species from a single patient

Tenofovir disoproxil fumarate mediates neuronal injury by inducing neurotoxicity

Cryptococcal meningitis and cerebral vasculitis in a patient with primary intestinal lymphangiectasia: a case report

A comparative study for optimization of MALDI-TOF MS identification of filamentous fungi

Occurrence and prevalence of Legionella species in dental chair units in Germany with a focus on risk factors

Bacteriophage therapy: are we running before we have learned to walk?

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage